Twist Bioscience Corp
NASDAQ:TWST
Twist Bioscience Corp
NASDAQ:TWST
Price:
48.64
USD
2.42%
Market Closed
Market Cap:
$3B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Twist Bioscience Corp
NASDAQ:TWST
|
US |
|
Fission Uranium Corp
TSX:FCU
|
CA |
|
China Resources Cement Holdings Ltd
HKEX:1313
|
HK |
|
Weimob Inc
HKEX:2013
|
CN |
|
I
|
IREIT Global
SGX:UD1U
|
SG |
|
Paycor HCM Inc
NASDAQ:PYCR
|
US |
|
District Metals Corp
XTSX:DMX
|
CA |
|
IVF Hartmann Holding AG
SIX:VBSN
|
CH |
|
Keppel Corporation Ltd
SGX:BN4
|
SG |
|
Kesar Terminals & Infrastructure Ltd
BSE:533289
|
IN |
|
M
|
Maagh Advertising & Marketing Services Ltd
BSE:543624
|
IN |
|
Beijing Shiji Information Technology Co Ltd
SZSE:002153
|
CN |
|
Rexford Industrial Realty Inc
NYSE:REXR
|
US |
|
Regis Resources Ltd
ASX:RRL
|
AU |
|
Nichias Corp
TSE:5393
|
JP |
|
P
|
Pelayaran Nasional Ekalya Purnamasari Tbk PT
IDX:ELPI
|
ID |
|
Mie Kotsu Group Holdings Inc
TSE:3232
|
JP |
|
Homag Group AG
F:HG1
|
DE |
|
P
|
Polygiene Group AB
STO:POLYG
|
SE |
Relative Value
The Relative Value of one
TWST
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 48.64 USD,
Twist Bioscience Corp
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
TWST Relative Value
HIDDEN
Multiples Across Competitors
TWST Competitors Multiples
Twist Bioscience Corp Competitors
Twist Bioscience Corp Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Twist Bioscience Corp
NASDAQ:TWST
|
3B USD | 7.6 | -38.9 | -25.3 | -20.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
366.3B USD | 6 | 87.5 | 14.5 | 20.2 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
355.9B USD | 109.6 | -1 710.6 | 15 890.6 | -1 794.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
190.8B USD | 5.2 | 24.7 | 14.3 | 14.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
171.6B USD | 5.8 | 20.2 | 12.6 | 15.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.6B USD | 9.6 | 29.2 | 22 | 23 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.2B USD | 5.5 | 17.6 | 13 | 14.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68B AUD | 3.2 | 34.9 | 11.5 | 14.5 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
